'Our business needs Irish Sea border reset'
A UK-EU summit is likely to pave the way for a deal which could substantially reduce the impact of the Irish Sea border.
The UK wants to reset its post-Brexit relationship with the European Union ( EU) after years of tension.
Monday's summit is expected to include an "agreement to agree" on trade issues, including the trade in food and agricultural products.
If a full agri-food deal follows, potentially later this year, that will reduce the need for checks and controls on products being sent from GB to Northern Ireland.
It could mean the end of 'Not for EU' labelling and the removal of most physical checks on goods.
One food business in Belfast said the reset cannot come soon enough and that immediate measures are needed to help small firms.
BBC News NI first spoke to the owners of Arcadia Deli in 2020 before the sea border started to be implemented. They have faced continuous struggles with the processes needed to get products from GB.
Co-owner Laura Graham-Brown said that new sea border rules on parcels have made the situation much worse in the last month.
"Our partners in England have decided they are not supplying Northern Ireland until further notice until they can get some clarification on how to make it easier," she said.
"That is our biggest distributor so it is starting to tell on our counter as it becomes increasingly empty."
She said she would welcome any deal that improves the situation but said something needs to change soon.
"All we want to do is sell cheese and olives. In order to keep stocking our shelves we need something to happen fairly quickly," she said.
There are no guarantees about the scope of the agreement being negotiated and, on its own, it would not eliminate the sea border.
Stuart Anderson from NI Chamber of Commerce said businesses would take time to analyse the detail of any deal.
"NI Chamber has been calling on the UK government to reach an agreement that is ambitious enough to substantially reduce bureaucracy for all operators in our agrifood supply chain," he said.
It comes as a poll from Queen's University Belfast suggests dwindling unionist support for Northern Ireland's current Brexit deal, the Windsor Framework.
Professor David Phinnemore said there was an "evident drop" in the already limited unionist support that exists for the Windsor Framework particularly among those identifying as "slightly unionist".
Support among that group has fallen from 51% to 26% over the last year.
Prof Phinnimore said: "If that trend is to be reversed, a closer UK-EU relationship needs to deliver on reducing obstacles to the GB-NI movement of goods."
The Labour government made a manifesto commitment to seek a new agri-food agreement with the EU which, it said, would aim to "eliminate most border checks created by the Tory Brexit deal".
The deal would apply to the UK as a whole but would have the biggest impact in Northern Ireland.
That is because NI is still effectively inside the EU's single market for goods but its supermarkets are mainly supplied from the UK.
The Centre for European Reform (CER), a think tank, said that an agri-food deal would not be of "great macroeconomic significance" for the UK as a whole but that NI would be a "major beneficiary".
It added: "The closer UK regulations come to those of the EU, the less is the need for border controls on goods crossing the Irish Sea from Great Britain to Northern Ireland."
The Irish Sea border continues to have an impact on Northern Ireland's politics and its economy.
It came about as the result of a Brexit deal between the EU and UK in 2019, which was revised in 2023, and is now known as the Windsor Framework.
It was agreed that the most practical way to keep the border open between NI and the Republic of Ireland was for NI to follow many EU laws on the regulation of goods.
This means that goods coming from the rest of the UK into NI face checks and controls to ensure they meet EU rules.
For many nationalists in NI, this is a necessary compromise to minimise the impact of Brexit on the island of Ireland.
For many unionists it is a constitutional affront which undermines NI's place in the UK.
The largest unionist party, the Democratic Unionist Party (DUP), prevented NI's power-sharing government from operating between 2022 and 2024 in protest.
Agri-food deals from the EU fall into two broad categories: New Zealand-style or Swiss-style.
The EU's deal with New Zealand means that each party recognises that the other has high food standards and so the frequency of checks on products and paperwork is reduced.
However, New Zealand still sets its own standards and a proportion of goods are still checked as they enter the EU.
By contrast there are no regulatory border controls for trade in agri-food products between Switzerland and the EU.
But the Swiss only have this deal because they agreed to follow EU rules almost to the letter, without much say in setting those rules.
Switzerland is obliged to modify its laws in response to changes in EU legislation, what is known as dynamic alignment, and accept oversight from the European Court of Justice.
A Swiss-style deal would mean controls on GB food products entering NI could be effectively ended.
The EU has previously said this deal would be on offer to the UK but the government had retained an ambivalent stance on whether it would accept this.
However in recent weeks ministers have been careful not to rule it out.
Such a deal will face opposition from Brexit supporters who say it would involve surrendering powers which were returned to the UK after it left the EU.
The Irish Sea is really two borders.
One deals with products' standards - making sure goods can be legally sold. The other deals with customs - making sure the correct tariffs have been paid.
An agri-food deal would go a long way to removing the standards border but it would leave the customs border untouched.
Businesses in GB would still have to make customs declarations for goods going to NI with the risk that goods would be delayed if the paperwork is incorrect.
How the NI Protocol became the Windsor Framework
New rules for GB to NI parcels to come into force
What is the new Northern Ireland Brexit trade deal?
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
European Penny Stocks Spotlight: Sinteza And Two Promising Picks
As the European markets continue to show resilience, with major stock indexes rising and inflation easing, investors are increasingly looking for opportunities in less conventional areas. Penny stocks, often overlooked due to their smaller market presence, can offer unique investment prospects when supported by solid financials. This article will explore three such stocks in Europe that stand out for their potential to deliver value and growth amid evolving economic conditions. Name Share Price Market Cap Financial Health Rating KebNi (OM:KEBNI B) SEK1.86 SEK504.35M ★★★★★★ Angler Gaming (NGM:ANGL) SEK3.67 SEK275.19M ★★★★★★ Cellularline (BIT:CELL) €2.97 €62.64M ★★★★★☆ Fondia Oyj (HLSE:FONDIA) €4.68 €17.5M ★★★★★★ Abak (WSE:ABK) PLN4.20 PLN10.78M ★★★★★★ Bredband2 i Skandinavien (OM:BRE2) SEK2.41 SEK2.31B ★★★★☆☆ Hifab Group (OM:HIFA B) SEK3.54 SEK215.37M ★★★★★★ Euroland Société anonyme (ENXTPA:MLERO) €3.26 €9.49M ★★★★★★ Deceuninck (ENXTBR:DECB) €2.195 €303.05M ★★★★★★ Netgem (ENXTPA:ALNTG) €0.952 €31.88M ★★★★★★ Click here to see the full list of 447 stocks from our European Penny Stocks screener. We'll examine a selection from our screener results. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Sinteza S.A. is a Romanian company involved in the production and marketing of basic organic chemical products, with a market cap of RON47.60 million. Operations: The company's revenue is primarily derived from the manufacture of other organic basic chemicals, amounting to RON0.68 million. Market Cap: RON47.6M Sinteza S.A., a Romanian chemical producer, remains pre-revenue with sales of RON0.10 million in Q1 2025, down from RON2.18 million the previous year. Despite its unprofitability and negative return on equity of -34.02%, the company has a satisfactory net debt to equity ratio of 14.7% and a cash runway exceeding three years due to positive free cash flow growth. However, Sinteza faces challenges with short-term assets not covering liabilities and increased losses over five years at 26.3% annually, alongside high share price volatility compared to other Romanian stocks. Click here and access our complete financial health analysis report to understand the dynamics of Sinteza. Learn about Sinteza's historical performance here. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Broadpeak Société anonyme designs and manufactures video delivery components for content and network service providers deploying video streaming services over various broadband networks worldwide, with a market cap of €19.35 million. Operations: Broadpeak Société anonyme generates revenue through three primary segments: Equipment (€3.55 million), Licenses and Services (€20.26 million), and Maintenance and Service as a Software (SaaS) (€15.57 million). Market Cap: €19.35M Broadpeak Société anonyme, with a market cap of €19.35 million, reported 2024 revenues of €39.38 million, showing slight growth from the previous year. Despite being unprofitable and having a negative return on equity of -19.96%, the company maintains sufficient cash runway for over three years due to positive free cash flow and short-term assets exceeding liabilities (€28.1M vs €21.8M). The firm trades at a significant discount to its estimated fair value and has not experienced meaningful shareholder dilution recently, although it remains highly volatile compared to French stocks with stable weekly volatility at 14%. Dive into the specifics of Broadpeak Société anonyme here with our thorough balance sheet health report. Evaluate Broadpeak Société anonyme's prospects by accessing our earnings growth report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Nextedia S.A. operates in France offering cybersecurity, cloud and digital workspace, and customer experience solutions, with a market cap of €23.17 million. Operations: The company generates revenue from its Direct Marketing segment, totaling €64.62 million. Market Cap: €23.17M Nextedia S.A., with a market cap of €23.17 million, demonstrates strong financial health in the penny stock arena. The company reported 2024 revenues of €64.62 million, reflecting growth from the previous year alongside a net income increase to €1.9 million from €0.7 million. Its debt is well covered by operating cash flow and interest payments are comfortably managed by EBIT, indicating robust financial management. Trading at a significant discount to its estimated fair value, Nextedia also benefits from seasoned board leadership and high-quality earnings growth outpacing industry averages, though its return on equity remains low at 6.1%. Jump into the full analysis health report here for a deeper understanding of Nextedia. Understand Nextedia's earnings outlook by examining our growth report. Click through to start exploring the rest of the 444 European Penny Stocks now. Contemplating Other Strategies? Outshine the giants: these 25 early-stage AI stocks could fund your retirement. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include BVB:STZ ENXTPA:ALBPK and ENXTPA:ALNXT. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Bloomberg
25 minutes ago
- Bloomberg
Eutelsat CEO Races to Raise Funds to Keep Starlink Rival Afloat
Europe's only Starlink alternative has to get cash fast to have any hope of challenging Elon Musk's provider of satellite-based internet services. Jean-François Fallacher, who took over as chief executive officer of Eutelsat Communications SA last week, is scrambling to get funds to save OneWeb, the constellation of low-Earth orbit (LEO) satellites that Eutelsat, based in a suburb of Paris, acquired in a $3.4 billion deal in 2023.
Yahoo
27 minutes ago
- Yahoo
ANGLE plc Announces Novel Discoveries Into the Biology of Cancer
PARSORTIX SYSTEM enableS novel DISCOVERIES into the biology of cancer Academic and translational research is the driving force behind the pipeline of next generation cancer therapeutics GUILDFORD, SURREY / / June 10, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the publication of three new peer-reviewed publications reporting first-in-class research into the biology of cancer and potential therapeutic targets using the Company's Parsortix system. Tumour cell release during surgery for prostate cancer1Professor Klaus Pantel and researchers from the University Medical Center Hamburg-Eppendorf published an article in the Journal of Experimental & Clinical Cancer Research, investigating tumour cell release into the local tumour vein and peripheral veins during surgery in early-stage prostate cancer patients. The study provides first evidence for substantial release of healthy and cancerous cells into the blood during prostatectomy surgery. This research opens a new avenue for the Parsortix system to study the important and under-investigated biology of tumour cell release during surgery to understand the risk they pose to patients, and for the development of strategies to minimise the spread of cancer. Tumour cell release during surgery for ovarian cancer2Professor John O'Leary and researchers from Trinity College Dublin have published similar findings in the European Journal of Surgical Oncology, investigating CTC enrichment from the local tumour vein and peripheral veins during surgery in rare epithelial ovarian carcinomas. They reported higher yields of CTCs and CTC clusters in the local tumour vein when compared to peripheral veins. The study also reported that CTCs were detected in early-stage patients, highlighting the risk of early tumour cell dissemination driving cancer progression even in the initial stages of disease. Overall, the authors state that assessing tumour cell release during surgery is a novel strategy to study the biology of this rare disease. Mechanical conditioning & metastatic implications3Professor Julie Lang and researchers from the Cleveland Clinic have published an article in Cancers, investigating biomechanical adaptions of cells that are associated with increased metastatic potential in breast cancer patients. They studied the expression of 1004 genes via RNA-sequencing that reflect how cancer cells respond to a stiff extracellular matrix described as a mechanical conditioning score. The Parsortix system was utilised to enrich and harvest CTCs from a metastatic cohort of breast cancer patients for analysis and compared these to primary and metastatic tissue. The study analysed RNA from CTCs rather than ctDNA to provide insight into gene expression. They state that: 'When analyzing shed ctDNA, there is no insight into gene expression, but rather only the presence of tumor-specific mutations, which is not directly reflective of dynamic tumor gene expression. In fact, only a very small percentage of DNA mutations are expressed, which is why circulating tumor DNA and RNA from CTCs are not parallel assays'. The study reported that the mechanical conditioning score increases progressively through the metastatic cascade (from the primary tumour to CTCs to the metastatic site) and is associated with increased metastatic potential. These are new insights into the biology of metastatic progression and may guide treatment selection with anti-fibrotic drugs. Overall, these publications further underscore the role of the Parsortix system in helping to advance our understanding of the biology of cancer which will ultimately advance oncology drug discovery and development. Already ANGLE's technology has enabled breakthrough research in a number of areas including the metastatic potential of CTC clusters, new potential biomarkers and a novel drug class. Academic and translational research discoveries made possible by the Parsortix system, have the potential to feed the pipeline of next generation personalised cancer diagnostics and therapeutics, as pharma companies increasingly collaborate with academia4. ANGLE's Chief Scientific Officer, Karen Miller, commented:"We are proud to see ANGLE's technology increasingly being exploited to make novel discoveries into the biology of cancer, which may eventually result in new treatment strategies. With advancing analytical capabilities beginning to realise the vast potential of the circulating tumour cell for its wealth of multiomic information, this contribution to the oncology pipeline will continue to grow. We congratulate these key opinion leaders on their outstanding work, and we look forward to more exciting discoveries in the future." 1. Emurlai, G. et al. Comparative analysis of circulating tumor cells in prostatic plexus and peripheral blood of patients undergoing prostatectomy. J. Exp. Clin. Cancer Res. 44, 143 (2025). 2. Lewis, F. et al. A pilot study evaluating the feasibility of enriching and detecting circulating tumour cells from peripheral and ovarian veins in rare epithelial ovarian carcinomas. Eur. J. Surg. Oncol. 51, (2025). 3. Mouneimne, G. et al. Mechanical Conditioning (MeCo) Score Progressively Increases Through the Metastatic Cascade in Breast Cancer via Circulating Tumor Cells. Cancers 17, 1632 (2025). 4. For further information: ANGLE plc +44 (0) 1483 343434 Andrew Newland, Chief Executive Ian Griffiths, Finance Director Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800 FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US) +44 (0) 203 727 1000 +1 (212) 850 5624 For Research Use Only. Not for use in diagnostic procedures. For Frequently Used Terms, please see the Company's website on Notes for editors About ANGLE plc ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays. Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product: The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions. This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@ or visit SOURCE: ANGLE plc View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data